- Amylyx Pharmaceuticals ( NASDAQ: AMLX ) on Friday said its Albrioza treatment for neurodegenerative disease amyotrophic lateral sclerosis (ALS) was now commercially available for use by patients in Canada.
- AMLX's Albrioza, also known as AMX0035, is an oral combination therapy that was shown to significantly slow disease progression and loss of functional decline in people living with ALS.
- Canada's drug regulator approved the ALS therapy , with conditions, in mid-June.
- A panel of the U.S. FDA is expected to meet in Sept. to discuss AMX0035.
- “We continue to work diligently to navigate reimbursement processes to pursue broad and equitable access to Albrioza across all provinces in Canada,” said AMLX's head of the country Chris Aiello in Friday's statement .
- Amylyx ( AMLX ) stock closed +5.5% at $26.30 on Thursday.
For further details see:
Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada